| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | ||
|---|---|---|---|---|---|---|
Cash flows from operating activities | ||||||
Net loss | ||||||
-122,447 | -85,288 | -60,121 | -30,291 | -20,263 | ||
Adjustments to reconcile net loss to net cash used in operating activities | ||||||
Depreciation and amortization | ||||||
356 | 175 | 89 | 67 | 42 | ||
Stock-based compensation | ||||||
16,449 | 10,225 | 3,394 | 1,391 | 389 | ||
Purchase of license agreement | ||||||
- | - | - | - | 181 | ||
Loss on disposal of fixed assets | ||||||
- | -8 | -6 | -18 | -2 | ||
Increase in fair value of warrant activity | ||||||
- | - | 41 | 82 | 85 | ||
Increase in fair value of Series B purchase option liability | ||||||
- | - | - | - | 4,773 | ||
Change in operating assets and liabilities | ||||||
Prepaid expenses and other assets | ||||||
219 | -113 | 253 | -216 | 789 | ||
Accounts payable | ||||||
248 | -1,002 | 1,578 | 1,477 | - | ||
Accrued Expenses | ||||||
6,042 | 1,446 | 4,709 | 1,871 | - | ||
Deferred Rent | ||||||
- | 16 | 38 | 28 | - | ||
Accounts payable and accrued expenses | ||||||
- | - | - | - | 1,735 | ||
Net cash used in operating activities | ||||||
-99,571 | -74,307 | -50,519 | -25,141 | -13,845 | ||
Cash flows from investing activities | ||||||
Purchases of property and equipment | ||||||
2,716 | 709 | 294 | 250 | 87 | ||
Net cash used in investing activities | ||||||
-2,716 | -709 | -294 | -250 | -87 | ||
Cash flows from financing activities | ||||||
Proceeds from stock options and warrants exercised | ||||||
2,705 | 1,797 | 215 | 7 | 53 | ||
Issuance costs for preferred share financings | ||||||
- | - | - | 249 | 140 | ||
Proceeds from public offering, net of underwriting fees and commissions | ||||||
- | 339,589 | 108,503 | - | - | ||
Payment of public offering costs | ||||||
- | 892 | 1,398 | - | - | ||
Net cash provided by financing activities | ||||||
2,705 | 340,494 | 107,320 | 49,758 | 33,176 | ||
Net change in cash and cash equivalents | ||||||
-99,582 | 265,478 | 56,507 | 24,367 | 19,244 | ||
Upfront project costs and other current assets in accounts payable and accrued expenses | ||||||
43 | 107 | - | - | - | ||
Accretion of redeemable convertible preferred stock | ||||||
- | - | 4,757 | 4,405 | 1,427 | ||
Exercise of Series B purchase option | ||||||
- | - | - | - | 6,708 | ||
Common stock issued for patent rights | ||||||
- | - | - | - | 181 | ||
Purchases of equipment in accounts payable and accrued expenses | ||||||
41 | 100 | - | - | - | ||
Conversion of preferred stock and preferred warrants to common stock and common warrants | ||||||
- | - | 112,545 | - | - | ||
Operating lease liabilities arising from obtaining right-of-use asset | ||||||
8,947 | - | - | - | - | ||
Series C Preferred Stock | ||||||
Proceeds from preferred stock | ||||||
- | - | - | 50,000 | - | ||